Articles tagged with: Marizomib
Press Releases»
Marizomib is a novel brain-penetrant proteasome inhibitor in development for patients with glioblastoma and relapsed and/or refractory multiple myeloma.
Toronto, ON and San Diego, CA (Press Release) – Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that Celgene Corporation, through an affiliate, has acquired the company’s assets related to its proteasome inhibitor, marizomib (MRZ), which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.
Under the terms of the agreement, Celgene will make an upfront payment plus additional …
News»

We're very glad to see you again, myeloma world.
Myeloma Morning was on brief hiatus while we helped with the Beacon's article about the recently published Ninlaro (ixazomib) clinical trial results.
Now that the Ninlaro article has been published, however, it's time to get back to normal Myeloma Morning business.
And there's a lot of it. In fact, there are almost 20 items in the list of new myeloma research at the end of today's report.
We obviously have to pace ourselves a …
News»

Good morning, myeloma world.
After a particularly busy inaugural edition of Myeloma Morning, today's edition doesn't have quite as much ground to cover. We'll be focusing most of today's discussion on just four new research studies that have been published.
That being said, the first of those studies is going to require more than the usual amount of attention.
That's because the study is a new International Myeloma Working Group (IMWG) consensus statement concerning high-risk cytogenetics – a subject of significant interest to almost everyone in myeloma world (
Press Releases»
-- Plenary Presentation at the 15th International Myeloma Workshop --
Toronto, ON and San Diego, CA (Press Release) – Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced preliminary results of a Phase 1 dose-escalation study of marizomib in combination with pomalidomide (POM) and low dose dexamethasone (Lo-DEX) in patients with relapsed and refractory multiple myeloma. The marizomib/POM/Lo-DEX combination was able to decrease myeloma proteins by at least 50 percent to achieve an overall response rate of 62 percent in …
Press Releases»
-- Company Presenting Today at Biocom’s Global Life Science Partnering Conference --
Toronto and San Diego (Press Release) - Triphase Accelerator Corporation today announced that marizomib, its novel, potent proteasome inhibitor, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA)'s Office of Orphan Products Development for the treatment of multiple myeloma. The orphan drug designation will provide Triphase with 7-year marketing exclusivity for marizomib and other benefits upon FDA approval.
“We are pleased that the FDA has granted orphan drug designation for the development of …
News»

In a recent review article published in the journal Clinical Cancer Research, two myeloma experts from the Dana-Farber Cancer Institute, Dr. Nikhil Munshi and Dr. Kenneth Anderson, review the latest strategies in the treatment of multiple myeloma.
In their article, the experts discuss newer therapies that appear to be promising in clinical and preclinical studies.
According to the physicians, combination therapies that specifically target a patient’s genetic form of the disease will be required for long-term disease control and ultimately a cure.
Some Historical Perspective
In their review article, Drs. Munshi and …
News»

Combined data from two recent Phase 1 clinical trials suggest that twice-weekly marizomib, with or without low-dose dexamethasone, may be effective for patients with relapsed or refractory multiple myeloma.
Dr. David Vesole from the John Theurer Cancer Center in Hackensack, New Jersey, who was not involved in the study, described marizomib as having “modest activity in relapsed/refractory myeloma.”
Dr. Paul Richardson from the Dana-Farber Cancer Institute in Boston presented the results at the American Society of Hematology (ASH) annual meeting in San Diego last month.
Marizomib (NPI-0052), which is being developed by …